Skip to content

Multi-omics study of gastrointestinal junction site cancer

Multi-omics study of gastrointestinal junction site cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400092787
Enrollment
Unknown
Registered
2024-11-22
Start date
2024-05-17
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal cancer

Interventions

Junction site cancer group:None
Non-binding site cancer group:None

Sponsors

The Second Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Those with informed consent; (2) Patients with malignant tumors in different locations (such as the gastroesophageal junction, pylorus, ileocecal area, rectosigmoid junction or recto-anal junction) clinically diagnosed through gastroscopy or colonoscopy and pathological examination; (3) The patient is generally in good condition and aged 18-75 years old; (4) No distant metastasis was found; (5) There are no serious complications before surgery.

Exclusion criteria

Exclusion criteria: (1) Various antibiotics or probiotics have been used 1 week before specimen collection; (2) Combined with other malignant tumors; (3) Have metabolic diseases, such as obesity, diabetes, various liver diseases, etc.; (4) There are family clustering cases. (5) Combined with severe heart, lung, kidney, and liver dysfunction.

Design outcomes

Primary

MeasureTime frame
Fecal high-throughput sequencing;Fecal Metabolomics;immunomics;transcriptome;

Secondary

MeasureTime frame
Incidence of tumors;

Countries

China

Contacts

Public ContactDeng Xiaorong

The Second Affiliated Hospital of Nanchang University

dengxr77@163.com+86 138 7088 9003

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026